trial

Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia

NCTId NCT00404573
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 375 (estimated)
Sponsored by Forest Laboratories
Primary completion 2007-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
375 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2006-11
Primary completion
2007-08
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Cariprazine (Vraylar)

Sponsors

Forest LaboratoriesLead Sponsor

Sites

1 total
St Louis, United States

Linked catalysts

1
Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia — primary completion2007-08

Facts & assertions

4 sourced
Enrollment
375
Phase
PHASE2
Primary Completion Date
2007-08
Status
COMPLETED
relationships
The graph out of here
drug
Cariprazine (Vraylar)
drug
lead_sponsor
Forest Laboratories
company
indication
Schizophrenia
indication
Schizophrenia
indication